Pure Storage vs uniQure N.V. Ordinary Shares — how do they compare? Pure Storage trades at $136.83 (market cap $47.15B), while uniQure N.V. Ordinary Shares trades at $21.53 (market cap $1.45B). The key difference: Pure Storage is far larger — about 32.5× uniQure N.V. Ordinary Shares's market cap, and Pure Storage is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pure Storage for 4 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| P | QURE | |
|---|---|---|
Market Cap | $47.15B | $1.45B |
Volume | 4,976,593 | 3,323,243 |
Sector | Technology | Health |
52-Week High | $156.97 | $70.59 |
52-Week Low | $56.99 | $9.03 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $46.37B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Everpure (P) trades at $156.97, up 1.07% today, near its 52-week high. The stock shows strong momentum with a bullish technical signal, supported by three consecutive quarterly earnings beats. Revenue grew from $3.17B in 2025 to $4.3B in 2026, with net income more than doubling. Recent news highlights a 147% six-month surge driven by AI-driven growth targets and positive investor sentiment.
Outlook remains optimistic due to robust earnings performance and AI expansion plans, but high valuation multiples (P/E 215) and overbought technical indicators pose risks. Analyst consensus is strongly bullish with a $141.47 price target, though insider selling and competitive pressures warrant caution for new investments.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →